Biomed | NXTGEN Hightech’s Post

🎖️Check out the Editor's Choice #Review "Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs" 👥by Virginia Metrangolo and Lars Engelholm Biotech Research & Innovation Centre (BRIC), University of Copenhagen Københavns Universitet - University of Copenhagen 🔗Link here: https://lnkd.in/evG8Bdif 🔶Antibody–drug conjugates (ADC) are targeted oncotherapeutics with the validated potential to create significant clinical impact. This comprehensive review covers the recent evolution of ADC design and development discussing molecular challenges and opportunities for further improvements.🔶

🔬 Revolutionizing Antibody Discovery: HITMASTER - A Microfluidic Marvel 🔬 We're thrilled to share further details of our recent collaboration with VERAXA Biotech GmbH , pioneering groundbreaking advancements in antibody discovery. 🌟 This partnership represents a significant leap in medical research, employing microfluidic technology to screen millions of antibody-secreting cells with unprecedented precision and speed. 🚀 The result? An innovative microfluidic droplet sorting chip, ensuring each therapeutic candidate's purity and precision without the risk of contamination. 💧 Join us on this visionary journey as we bridge innovation with impact, shaping a future where every therapeutic potential is within our grasp. 💡 Partners involved in this project are temicon GmbH, Micronit, and JOANNEUM RESEARCH. Their invaluable contributions span from micro- and nanostructuring expertise to advanced microfluidic solutions and research innovation. Together, we're not just developing technology; we're crafting a synergy that accelerates the frontiers of scientific exploration and healthcare possibilities. 🤝🔬 👉 Dive into the details of our collaboration and the path-breaking technology on our blog: https://lnkd.in/did4-rNM #Microfluidics #Innovation #HealthcareTechnology #AntibodyDiscovery #Collaboration #FutureOfMedicine #ScientificCollaboration #MicroNanoTechnology #ResearchInnovation #MIHfamily This project is part of NextGenMicrofluidcs (https://lnkd.in/e7rsPRa). NextGenMicrofluidics has received funding from the European Union’s HORIZON 2020 research & innovation programme under grant agreement no. 862092.

📚 SCIENTIFIC POSTER | SPAchip® technology: A novel reliable method for long-term intracellular calcium detection in real time 🔔ARRAYS FOR CELL NANODEVICES, SL - A4CELL presented a poster during the last SLAS (Society for Laboratory Automation and Screening) exhibition alongside our partners, Biobide, Your Zebrafish Partner and Fundacion MEDINA 🧫This poster showcases our #SPAchip platform for the detection of free #calcium within living cells. ⚡Key messages: • These silicon microchips, easily internalized inside cells, act as miniature laboratories, measuring calcium concentrations in real time. • The technology has been validated in various cell lines and zebrafish embryos, demonstrating its potential for in vitro and in vivo applications. • SPAchip® technology enables the dynamic measurement of intracellular parameters over extended periods, without compromising cell viability, making it a valuable tool for drug discovery and personalized medicine. • The technology is compatible with other cellular information, including morphological parameters and comparison with extracellular media, as it remains in the cytosol without producing cytotoxic effects. • With great versatility in several fluorescence reading platforms and two fluorescence emission colors, this technology has high potential not only in vitro but also in vivo and single cell applications, offering valuable insights into the mechanism of action of compounds during drug discovery campaigns. 🤝 We're eager to explore the potential of SPAchip® further and invite you to join us in this journey. For more details, feel free to reach out or comment below. #LiveCellAnalysis #DrugDiscovery #BiomedicalResearch #SLAS2024 #Innovation

Last week's meeting at the Rotterdam Science Tower was a landmark event for Delta Diagnostics and our partners. The purpose of this gathering was clear: to explore the innovative potential of our label-free biosensing technology and to strengthen our commitment to making this technology widely accessible. We are driven by a mission to democratize biosensing technology, ensuring that researchers from institutions of any size and funding level can benefit from our advanced solutions. Our photonic integrated circuit-based biosensors represent a leap forward, offering high-throughput, multiplexed, and label-free detection capabilities. This technology stands to change the way researchers approach biosensing, making complex analyses simpler, faster, and more cost-effective. Our distributor partners joined from across Europe, each bringing their unique perspective and expertise to the table. Claus Dall Larsen from LABLAB Aps (Denmark), Peter Blom of XboXLab AS (Sweden/Norway/Finland), Urs Wegmann and Malika Mühlebach from LABFORCE (Switzerland), and Josef Uskoba from iBiotech (Czech Republic/Hungary/Slovakia) all shared their insights on how we can better support them and tap into the opportunities presented by our biosensing technology. The discussions focused on collaborative strategies to enhance distributor support and to navigate the challenges of bringing sour tech to scientists. Our collective vision, "Enabling More For Less," highlights our commitment to breaking down the barriers to advanced biosensing tools, ensuring that these innovations are accessible to all researchers. It was a greatr step forward in a shared journey towards transforming biosensing technology and ensuring that every researcher has the opportunity to explore and discover without limitations. #photonics #biosensing #lifesciences

Evaxion Biotech A/S, a clinical-stage TechBio company, has presented advancements in its AI-Immunology™ platform, specifically focusing on the improved performance of its EvaxMHC component. This announcement was made at the 32nd Intelligent Systems for Molecular Biology (#ISMB2024) conference held in Montreal, Canada, from July 12-16, 2024. Key advancements presented include: Utilization of a state-of-the-art deep-learning framework to enhance the accuracy of peptide-MHC predictions. Implementation of three new strategies: a unified representation for MHC class I and II molecules, a deep transformer encoder-decoder architecture, and a generative adversarial network (GAN) pretraining mechanism. Improved vaccine designs demonstrated in preclinical studies. Read full news via link in the comments #biopharmatrend #artificialintelligence #biotech Image credit: iStock, buzbuzzer

 📌 Join Nanolumi and Luminicell at TechInnovation 2023, organised by IPI, from 31 October to 2 November at Marina Bay Sands!   The three-day event marries #business needs and #technology by bringing together an exceptional gathering of technology seekers, providers, and industry leaders from all over the world.   Luminicell offers key enabling solutions to accelerate end-to-end translational biomedical research. Empowering researchers to conduct a wide range of experiments, including #invitro #2D and #3Dcell, as well as #invivo #biodistribution studies. Making it an excellent choice for determining cell fate and distributions, which are essential data in #preclinical animal studies and associated workflows.   Curious to know more? Visit us at the startup booth S7.   #Techinnovation2023 #IPI #Luminicell #Singapore

Interesting and excellent application of this execution technology.

Frontier Science - Chemoproteomics w/ Daniel Nomura - Professor @ University of California, Berkeley Tune into our enlightening podcast episode featuring Prof. Daniel Nomura from University of California, Berkeley. He discusses his transformative work at Frontier Medicines, where they're pioneering new frontiers in precision medicine by targeting elusive, disease-causing proteins. Prof. Nomura shares insights on chemoproteomics, covalent drug discovery, and the integration of machine learning to develop groundbreaking cancer treatments, especially targeting the KRAS G12C mutation. This episode offers a rare glimpse into the seamless blend of academic research and biotech entrepreneurship, driven by personal passion and scientific curiosity. 👉 Don't miss this deep dive into the innovative approaches reshaping drug discovery. https://buff.ly/47W13H5 Shoutout: The Column Group, Andreessen Horowitz, Droia Ventures, Vicinitas Therapeutics, University of California, San Francisco & more. #DrugDiscovery #PrecisionMedicine #ChemicalBiology #Biotech #InnovativeResearch